Msh Pharma
MSH Pharma is a Quebec-based B2B CDMO specializing in contract manufacturing of suppositories, vaginal ovules, and non-sterile liquid pharmaceutical products. The firm serves innovative and generic pharmaceutical companies with integrated development, technology transfer, and clinical batch services.
- Company typePrivate
- Founded2023
- HeadquartersMont-saint-hilaire, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Msh Pharma does
MSH Pharma operates as a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical development and manufacturing services for non-sterile dosage forms, including suppositories, vaginal ovules, solutions, and suspensions. The company is headquartered at 597 boulevard Sir-Wilfrid-Laurier, Mont-Saint-Hilaire, Quebec, Canada (J3H 6C4), operating a single integrated facility covering more than 115,000 square feet and housing manufacturing, development, packaging, analytics, and warehousing operations. Core production technology includes three fully automated suppository and ovule filling units delivering a nominal capacity of 60,000 ovules per hour with batch-size flexibility from 1 kg to 750 kg for solid dosage forms and 1 L to 4,000 L for non-sterile liquids in bottle sizes from 20 mL to 500 mL. The facility exceeds the latest CGMP (Current Good Manufacturing Practice) requirements and holds compliance recognition from Health Canada, the US FDA, and the European Medicines Agency. The firm additionally holds authorizations to manufacture controlled-substance products and operates an integrated in-house pharmaceutical analysis laboratory equipped with stability chambers for stability studies and method development.\n\nRevenue is generated through three primary service streams: contract development and manufacturing (CDMO) engagements covering preformulation and formulation development, API procurement, manufacturing procedure design and validation, packaging design, analytic services, stability studies, and regulatory filing support; technology transfer services to relocate manufacturing procedures into the Mont-Saint-Hilaire facility; and clinical batch production for clients in the development phase. Commercial activity is sales-led, with a dedicated Business Development Director (Alain Huneault) engaging enterprise pharmaceutical clients and a project manager assigned to each engagement to coordinate delivery against scope, timeline, and budget. Pricing is quote-based and negotiated individually per project, with no public pricing disclosed. Two primary customer segments are targeted: innovative brand-name pharmaceutical developers and generic drug manufacturers, both pursuing specialized non-sterile dosage forms. Distribution is purely direct-to-business; the firm does not sell to retail or marketplace channels. The company employs 51-100 staff and is privately held with no public ticker.\n\nMSH Pharma traces its operational history to a Canadian manufacturing site created in 1994 under Axcan, which subsequently operated under the Aptalis (2011), Adare (2015), and Endoceutics (2017) identities before adopting the current MSH Pharma Inc. corporate name in 2023. The firm manufactures the Intrarosa prasterone vaginal ovule for Endoceutics and holds multiple long-term contracts with reputable, unnamed pharmaceutical companies for both brand-name and generic drug products. Public-facing channels are limited to a corporate website and LinkedIn presence, with customer acquisition driven primarily by direct outreach and contact-form inquiries. The company claims the largest suppository and vaginal ovule manufacturing capacity in North America for both brand-name and generic drug products.
Msh Pharma firmographics
Firmographics- Name
- Msh Pharma
- Legal name
- MSH PHARMA INC.
- Website
- https://mshpharma.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MSH Pharma is a Quebec-based B2B CDMO specializing in contract manufacturing of suppositories, vaginal ovules, and non-sterile liquid pharmaceutical products. The firm serves innovative and generic pharmaceutical companies with integrated development, technology transfer, and clinical batch services.
- Ownership category
- akta.pro rank
Msh Pharma industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Msh Pharma is headquartered
LocationHeadquarters
- HQ city
- Mont-saint-hilaire
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Msh Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Development and Manufacturing (CDMO): MSH Pharma operates as a CDMO providing comprehensive pharmaceutical development and manufacturing services including preformulation and formulation development, API procurement, manufacturing procedure design and validation, packaging design, technology transfer, analytic services, stability studies, and regulatory filing support. The company holds long-term contracts with reputable pharmaceutical companies.
- Clinical Batch Production: Production of clinical batches for pharmaceutical companies in development phase, leveraging facility and equipment flexibility.
- Technology Transfer Services: Pharmaceutical technology transfer services ensuring efficient transfer of manufacturing procedures to MSH facilities, supported by modern facilities and technical expertise.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Msh Pharma product offering
Product offeringCore offering
MSH Pharma is a Canadian Contract Development and Manufacturing Organization (CDMO) that contract manufactures non-sterile pharmaceutical dosage forms — primarily suppositories, vaginal ovules, and liquid products (solutions and suspensions) — for brand-name, generic, and over-the-counter pharmaceutical companies. The company offers integrated services spanning formulation development, API procurement, technology transfer, analytical testing, clinical batch production, and regulatory filing support. Its 115,000+ sq ft Mont-Saint-Hilaire facility houses the largest suppository and vaginal ovule manufacturing capacity in North America.
Product overview
MSH PHARMA is a Contract Development and Manufacturing Organization (CDMO) offering a unified portfolio of pharmaceutical manufacturing services. The core offerings center on three main product categories: suppositories and vaginal ovules (with the largest manufacturing capacity in North America), non-sterile solutions and suspensions, and controlled substances manufacturing. These manufacturing capabilities are supported by integrated services including CDMO development services (preformulation, formulation, API procurement, packaging design), technology transfer, analytic support with an in-house pharmaceutical lab, and clinical batch production. The company positions itself as a one-stop partner for pharmaceutical development from formulation through commercial manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- Suppositories and Vaginal Ovules Manufacturing Contract manufacturing of suppositories and vaginal ovules for brand-name and generic pharmaceutical products, leveraging fully automated facilities with a nominal capacity of 60,000 ovules per hour across three filling units.
- Non-Sterile Solutions and Suspensions Manufacturing Contract manufacturing of non-sterile liquid pharmaceutical products in solution and suspension forms, accommodating batch sizes from 1 L to 4,000 L and bottle sizes from 20 ml to 500 ml in glass or plastic with various cap types, plus nitrogen blanketing and induction sealing.
- Controlled Substances Manufacturing Handling and contract manufacturing of pharmaceutical products containing controlled substances, with all necessary facilities and authorizations in place for compliant production.
- CDMO Services (Contract Development and Manufacturing) End-to-end contract development and manufacturing organization services including preformulation and formulation development, API procurement, manufacturing procedure design and validation, packaging design, analytic services, stability studies, and regulatory filing support for pharmaceutical clients.
- Technology Transfer Pharmaceutical technology transfer services ensuring efficient transfer of manufacturing procedures to MSH Pharma's facilities, supported by modern equipment and technical expertise, with assigned project managers for coordination.
- Analytic Support Integrated pharmaceutical analysis services from an in-house laboratory covering primary material analysis, packaging component testing, finished product analysis, method development and validation, and stability chamber studies.
- Clinical Batch Production Clinical batch production services utilizing flexible facilities and equipment to support clinical trial manufacturing needs for pharmaceutical clients in development phase.
Quantifiable outcome
- Nominal capacity of 60,000 ovules per hour
- +2 more outcomes
Companies that use Msh Pharma
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Msh Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Msh Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Reputable pharmaceutical companies (multiple long-term contracts)coreMSH Pharma holds several long-term contracts with reputable pharmaceutical companies for development and manufacturing of brand-name and generic pharmaceutical products. These are strategic partnerships involving collaborative product development, manufacturing services, and ongoing supply relationships for specialized dosage forms including suppositories, vaginal ovules, and liquid products.
Scale indicators6 records
Recent moves6 records
Expansion highlights4 records
Msh Pharma competitors and assessment
Company assessmentDirect peers
- Adare Pharmaceuticals: Former owner of the Mont-Saint-Hilaire site (2015-2017) and a CDMO specializing in oral solid doses and niche dosage forms; directly comparable in customer base, capabilities, and dosage-form portfolio.
- Catalent: Global CDMO with dedicated softgel and specialty dose-form manufacturing, including suppository capabilities; competes head-to-head with MSH for branded and generic suppository/ovule outsourcing programs.
- Unither Pharmaceuticals: French-headquartered CDMO with established suppository, ovule, and sterile liquid manufacturing; serves similar branded and generic pharma customers across regulated markets.
- CordenPharma: Full-service CDMO offering solid dose, semi-solid, and liquid manufacturing including suppositories for global pharma; overlaps MSH on non-sterile specialty dosage forms and EU/NA regulatory reach.
- Cambrex: North American CDMO offering API and finished dose development/manufacturing across small molecules; overlaps MSH on contract manufacturing for specialty pharmaceutical products.
- Pillar5 Pharma: Canadian CDMO specializing in solid, semi-solid, and liquid pharmaceutical manufacturing; same North American footprint, overlapping customer base of branded and generic pharma.
Broad incumbents
- Almac Group: Global CDMO providing pharmaceutical development, manufacturing, and analytical services; competes with MSH for outsourced non-sterile formulation and commercial supply programs.
- Recipharm: European-headquartered CDMO with broad solid, semi-solid, and sterile manufacturing capabilities; competes with MSH for outsourced non-sterile liquid and specialty dose programs.
- Patheon (Thermo Fisher Scientific): One of the largest global CDMOs offering end-to-end development and commercial manufacturing across virtually all dosage forms, including semi-solids and liquids; a scale incumbent MSH competes against for large pharma outsourcing contracts.
- Aenova Group: European CDMO leader in solid, semi-solid, and liquid dose manufacturing; comparable in customer profile (mid-to-large branded and generic pharma) and regulatory scope (FDA, EMA).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Msh Pharma social profiles
Digital presenceMsh Pharma compliance and trust
Trust signalCompliance4 records
Msh Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Msh Pharma leadership team
Management profileNumber of profiles
Profiles6 records
Msh Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Msh Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Msh Pharma
What does Msh Pharma do?
MSH Pharma is a Canadian Contract Development and Manufacturing Organization (CDMO) that contract manufactures non-sterile pharmaceutical dosage forms — primarily suppositories, vaginal ovules, and liquid products (solutions and suspensions) — for brand-name, generic, and over-the-counter pharmaceutical companies. The company offers integrated services spanning formulation development, API procurement, technology transfer, analytical testing, clinical batch production, and regulatory filing support. Its 115,000+ sq ft Mont-Saint-Hilaire facility houses the largest suppository and vaginal ovule manufacturing capacity in North America.
Is Msh Pharma a public or private company?
Msh Pharma is a private company. It is classified as unknown and is currently operating.
When was Msh Pharma founded?
Msh Pharma was founded in 2023. It employs 11 to 50 people.
Where is Msh Pharma based?
Msh Pharma is headquartered in Mont-saint-hilaire, Canada, in the North America region.
How does Msh Pharma make money?
Three revenue lines are on record. Contract Development and Manufacturing (CDMO) is the primary driver. The others are clinical Batch Production and technology Transfer Services.
Who are Msh Pharma's main competitors?
Direct peers on record are Adare Pharmaceuticals, Catalent, Unither Pharmaceuticals, CordenPharma, Cambrex and Pillar5 Pharma. Broad incumbents are Almac Group, Recipharm, Patheon (Thermo Fisher Scientific) and Aenova Group.
Does Msh Pharma have an API?
No public API is recorded for Msh Pharma.
What industry is Msh Pharma in?
Msh Pharma's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.